Bal Pharma Limited (BALPHARMA.NS)
INR 105.7
(1.63%)
INR 105.7
(1.63%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.26 Billion INR | -2.44% |
| 2022 | 1.29 Billion INR | 22.71% |
| 2021 | 1.05 Billion INR | -4.85% |
| 2020 | 1.1 Billion INR | -7.22% |
| 2019 | 1.19 Billion INR | -1.24% |
| 2018 | 1.21 Billion INR | 12.88% |
| 2017 | 1.07 Billion INR | 21.23% |
| 2016 | 884.74 Million INR | 10.02% |
| 2015 | 804.13 Million INR | 94.76% |
| 2014 | 412.87 Million INR | -13.44% |
| 2013 | 476.95 Million INR | 15.48% |
| 2012 | 413.02 Million INR | -13.22% |
| 2011 | 475.93 Million INR | -15.59% |
| 2010 | 563.85 Million INR | 6.46% |
| 2009 | 529.66 Million INR | 15.63% |
| 2008 | 458.07 Million INR | 8.42% |
| 2007 | 422.48 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q3 | 83.79 Million INR | -94.0% |
| 2023 Q4 | 1.26 Billion INR | 1407.96% |
| 2023 Q2 | 1.39 Billion INR | 1735.23% |
| 2023 Q1 | 76.12 Million INR | -94.12% |
| 2023 FY | 1.26 Billion INR | -2.44% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 1.36 Billion INR | 2424.58% |
| 2022 Q1 | 53.93 Million INR | -94.89% |
| 2022 FY | 1.29 Billion INR | 22.71% |
| 2022 Q4 | 1.29 Billion INR | 0.0% |
| 2021 Q1 | 56.53 Million INR | -94.9% |
| 2021 Q2 | 994.96 Million INR | 1659.87% |
| 2021 FY | 1.05 Billion INR | -4.85% |
| 2021 Q4 | 1.05 Billion INR | 0.0% |
| 2020 Q4 | 1.1 Billion INR | 1584.17% |
| 2020 Q3 | 65.86 Million INR | -94.3% |
| 2020 Q2 | 1.15 Billion INR | 3192.49% |
| 2020 Q1 | 35.06 Million INR | -97.07% |
| 2020 FY | 1.1 Billion INR | -7.22% |
| 2019 Q3 | 45.51 Million INR | -95.98% |
| 2019 FY | 1.19 Billion INR | -1.24% |
| 2019 Q2 | 1.13 Billion INR | 2517.78% |
| 2019 Q1 | 43.24 Million INR | -96.43% |
| 2019 Q4 | 1.19 Billion INR | 2526.95% |
| 2018 Q4 | 1.21 Billion INR | 0.0% |
| 2018 FY | 1.21 Billion INR | 12.88% |
| 2017 FY | 1.07 Billion INR | 21.23% |
| 2017 Q4 | 1.07 Billion INR | 0.0% |
| 2016 Q1 | 37.6 Million INR | -95.32% |
| 2016 FY | 884.74 Million INR | 10.02% |
| 2016 Q4 | 884.74 Million INR | 0.0% |
| 2016 Q2 | 787.93 Million INR | 1995.23% |
| 2015 Q3 | 65.87 Million INR | -89.61% |
| 2015 FY | 804.13 Million INR | 94.76% |
| 2015 Q4 | 804.13 Million INR | 1120.72% |
| 2015 Q1 | 54.94 Million INR | -86.69% |
| 2015 Q2 | 634.28 Million INR | 1054.42% |
| 2014 Q2 | 423.07 Million INR | 1298.95% |
| 2014 FY | 412.87 Million INR | -13.44% |
| 2014 Q4 | 412.87 Million INR | 622.72% |
| 2014 Q3 | 57.12 Million INR | -86.5% |
| 2014 Q1 | 30.24 Million INR | -93.66% |
| 2013 Q2 | 439.72 Million INR | 829.96% |
| 2013 Q4 | 476.95 Million INR | 1475.0% |
| 2013 FY | 476.95 Million INR | 15.48% |
| 2013 Q1 | 47.28 Million INR | -88.55% |
| 2013 Q3 | 30.28 Million INR | -93.11% |
| 2012 Q2 | 441.78 Million INR | 0.0% |
| 2012 FY | 413.02 Million INR | -13.22% |
| 2012 Q4 | 413.02 Million INR | 0.0% |
| 2011 Q4 | 475.93 Million INR | 0.0% |
| 2011 FY | 475.93 Million INR | -15.59% |
| 2010 FY | 563.85 Million INR | 6.46% |
| 2009 FY | 529.66 Million INR | 15.63% |
| 2008 FY | 458.07 Million INR | 8.42% |
| 2007 FY | 422.48 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 67.315% |
| Hester Biosciences Limited | 2.29 Billion INR | 44.84% |
| Aarti Drugs Limited | 5.54 Billion INR | 77.227% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 51.623% |
| Albert David Limited | -278.36 Million INR | 553.916% |
| Alembic Limited | 66.9 Million INR | -1788.731% |
| Alkem Laboratories Limited | -1.6 Billion INR | 178.511% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -449.534% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 61.698% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 6950.054% |
| Brooks Laboratories Limited | 49.48 Million INR | -2453.422% |
| Eris Lifesciences Limited | 13.8 Billion INR | 90.848% |
| FDC Limited | -57.75 Million INR | 2287.909% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 144.45% |
| Gufic Biosciences Limited | 3.19 Billion INR | 60.443% |
| Hikal Limited | 7.96 Billion INR | 84.14% |
| Ind-Swift Limited | 9.5 Billion INR | 86.711% |
| Innova Captab Limited | 2.33 Billion INR | 45.857% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 214.734% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 190.908% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 95.333% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 1089.957% |
| Lupin Limited | 19.38 Billion INR | 93.482% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | -29.488% |
| Medico Remedies Limited | 78.67 Million INR | -1506.011% |
| Morepen Laboratories Limited | -231.17 Million INR | 646.584% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 79.479% |
| Orchid Pharma Limited | -1.31 Billion INR | 196.173% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 153.814% |
| RPG Life Sciences Limited | -364.7 Million INR | 446.466% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -952.625% |
| Sigachi Industries Limited | 859.94 Million INR | -46.934% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 87.404% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -771.566% |
| Themis Medicare Limited | 764.96 Million INR | -65.18% |
| Unichem Laboratories Limited | 931.91 Million INR | -35.587% |
| Vaishali Pharma Limited | 119.13 Million INR | -960.613% |
| Wanbury Limited | 1.1 Billion INR | -14.259% |
| Windlas Biotech Limited | -273.04 Million INR | 562.775% |
| ZIM Laboratories Limited | 983.6 Million INR | -28.462% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 130.425% |
| Ipca Laboratories Limited | 11.41 Billion INR | 88.931% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 101.744% |
| Venus Remedies Limited | -267.7 Million INR | 572.006% |
| Sakar Healthcare Limited | 790.93 Million INR | -59.755% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 65.788% |
| Divi's Laboratories Limited | -39.77 Billion INR | 103.177% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 125.208% |
| Mankind Pharma Limited | -1.74 Billion INR | 172.272% |
| Sequent Scientific Limited | 4.17 Billion INR | 69.761% |
| Laurus Labs Limited | 24.35 Billion INR | 94.812% |
| Neuland Laboratories Limited | -214.05 Million INR | 690.289% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 55.212% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 129.486% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 67.7% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 607.878% |
| Wockhardt Limited | 18.27 Billion INR | 93.084% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 90.215% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 209.139% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 444.728% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 122.942% |
| Shilpa Medicare Limited | 9.06 Billion INR | 86.068% |
| Valiant Laboratories Limited | 649.9 Million INR | -94.423% |
| Ajanta Pharma Limited | -954.9 Million INR | 232.324% |
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -324.613% |
| Granules India Limited | 9.28 Billion INR | 86.394% |
| Medicamen Biotech Limited | 160.31 Million INR | -688.169% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -2634.329% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.743% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 96.03% |
| NATCO Pharma Limited | -5.81 Billion INR | 121.722% |
| Suven Life Sciences Limited | -1.63 Billion INR | 177.391% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 34.629% |
| Strides Pharma Science Limited | 23.25 Billion INR | 94.567% |
| Indoco Remedies Limited | 6.47 Billion INR | 80.489% |
| Alpa Laboratories Limited | 35.36 Million INR | -3473.116% |
| Lasa Supergenerics Limited | 205.79 Million INR | -513.978% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 234.164% |